Lazard Asset Management
AUPH icon

Lazard Asset Management’s Aurinia Pharmaceuticals AUPH Stock Holding History

Lazard Asset Management’s Portfolio AUPH Stock Details AUPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$2.04M Sell
137,355
-106,820
-44% -$1.56M ﹤0.01% 883
2025
Q4 		$3.89M Sell
244,175
-111,494
-31% -$1.58M 0.01% 632
2025
Q3 		$3.93M Sell
355,669
-443,089
-55% -$4.84M 0.01% 645
2025
Q2 		$6.76M Sell
798,758
-446,274
-36% -$3.58M 0.01% 647
2025
Q1 		$10M Buy
1,245,032
+648,643
+109% +$5.25M 0.02% 493
2024
Q4 		$5.36M Buy
596,389
+461,430
+342% +$3.76M 0.01% 628
2024
Q3 		$989K Buy
134,959
+116,093
+615% +$720K ﹤0.01% 1079
2024
Q2 		$107K Buy
+18,866
New +$99.4K ﹤0.01% 1733
2024
Q1 		– Sell
-8,641
Closed -$76K – 2049
2023
Q4 		$76K Sell
8,641
-46,787
-84% -$385K ﹤0.01% 1762
2023
Q3 		$430K Buy
55,428
+32,137
+138% +$314K ﹤0.01% 1185
2023
Q2 		$224K Buy
+23,291
New +$242K ﹤0.01% 1312
2023
Q1 		– Sell
-8,865
Closed -$38K – 2294
2022
Q4 		$38K Sell
8,865
-106
-1% -$615 ﹤0.01% 1921
2022
Q3 		$67K Buy
8,971
+3,671
+69% +$31.8K ﹤0.01% 1660
2022
Q2 		$53K Hold
5,300
– – ﹤0.01% 1784
2022
Q1 		$65K Buy
5,300
+3,298
+165% +$51K ﹤0.01% 1610
2021
Q4 		$45K Buy
+2,002
New +$47.4K ﹤0.01% 1781
2021
Q2 		– Sell
-3,520
Closed -$45K – 1958
2021
Q1 		$45K Buy
+3,520
New +$51.1K ﹤0.01% 1477

Other funds holding AUPH

TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $185B AUM 39.58% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Lazard Asset Management's AUPH Position: Q1 2026 in Review

Lazard Asset Management reduced its Aurinia Pharmaceuticals (AUPH) stake by 44% in Q1 2026, selling an estimated $1.56M and leaving 137,355 shares worth $2.04M. The position accounts for ﹤0.01% of the portfolio, ranked #883.

Lazard Asset Management first reported a position in AUPH in Q1 2021 and has held it in 17 quarters since. The position peaked at $10M in Q1 2025. 259 funds tracked by Wall St. Rank hold AUPH as of Q1 2026.

  • Lazard Asset Management held 137,355 shares of Aurinia Pharmaceuticals worth $2.04M as of Q1 2026.
  • Lazard Asset Management sold 106,820 Aurinia Pharmaceuticals shares in Q1 2026, an estimated $1.56M.
  • Aurinia Pharmaceuticals made up ﹤0.01% of Lazard Asset Management's portfolio in Q1 2026, its #883 holding.
  • Lazard Asset Management first reported a position in Aurinia Pharmaceuticals in Q1 2021 and has held it in 17 quarters since.
  • Lazard Asset Management's Aurinia Pharmaceuticals position peaked at $10M in Q1 2025.
  • 259 funds tracked by Wall St. Rank held Aurinia Pharmaceuticals as of Q1 2026.

Based on Lazard Asset Management's 13F filing for Q1 2026, filed 15 May 2026.